These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38287621)

  • 1. Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure.
    Arends S; de Wolff L; van Nimwegen JF; Verstappen GMPJ; Vehof J; Bombardieri M; Bowman SJ; Pontarini E; Baer AN; Nys M; Gottenberg JE; Felten R; Ray N; Vissink A; Kroese FGM; Bootsma H
    Lancet Rheumatol; 2021 Aug; 3(8):e553-e562. PubMed ID: 38287621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study).
    van Nimwegen JF; Mossel E; van Zuiden GS; Wijnsma RF; Delli K; Stel AJ; van der Vegt B; Haacke EA; Olie L; Los LI; Verstappen GM; Pringle SA; Spijkervet FKL; Kroese FGM; Vissink A; Arends S; Bootsma H
    Lancet Rheumatol; 2020 Mar; 2(3):e153-e163. PubMed ID: 38263653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
    Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial.
    de Wolff L; van Nimwegen JF; Mossel E; van Zuiden GS; Stel AJ; Majoor KI; Olie L; Los LI; Vissink A; Spijkervet FKL; Verstappen GMPJ; Kroese FGM; Arends S; Bootsma H
    Semin Arthritis Rheum; 2022 Apr; 53():151955. PubMed ID: 35091325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
    Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome.
    de Wolff L; Arends S; Pontarini E; Bombardieri M; Bowman SJ; Bootsma H
    Clin Exp Rheumatol; 2021; 39 Suppl 133(6):100-106. PubMed ID: 34796851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's.
    Cooper C; Wratten S; Williams-Hall R; Bookman AAM; Ndife B; Hueber W; Goswami P
    Rheumatol Ther; 2022 Dec; 9(6):1499-1515. PubMed ID: 36114443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.
    van der Heijden EHM; Blokland SLM; Hillen MR; Lopes APP; van Vliet-Moret FM; Rosenberg AJWP; Janssen NG; Welsing PMJ; Iannizzotto V; Tao W; Pandit A; Barone F; Kruize AA; Radstake TRDJ; van Roon JAG
    Lancet Rheumatol; 2020 May; 2(5):e260-e269. PubMed ID: 38273473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
    Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM
    Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks.
    Tsuboi H; Matsumoto I; Hagiwara S; Hirota T; Takahashi H; Ebe H; Yokosawa M; Hagiya C; Asashima H; Takai C; Miki H; Umeda N; Kondo Y; Ogishima H; Suzuki T; Hirata S; Saito K; Tanaka Y; Horai Y; Nakamura H; Kawakami A; Sumida T
    Mod Rheumatol; 2015 Mar; 25(2):187-93. PubMed ID: 25211401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome Endocrinopathy) and ROSE II trials.
    Tsuboi H; Toko H; Honda F; Abe S; Takahashi H; Yagishita M; Hagiwara S; Ohyama A; Kondo Y; Nakano K; Tanaka Y; Shimizu T; Nakamura H; Kawakami A; Fujieda Y; Atsumi T; Suzuki Y; Kawano M; Nishina N; Kaneko Y; Takeuchi T; Kobayashi H; Takei M; Ogasawara M; Tamura N; Takasaki Y; Yokota K; Akiyama Y; Mimura T; Murakami K; Mimori T; Ohshima S; Azuma N; Sano H; Nishiyama S; Matsumoto I; Sumida T
    Mod Rheumatol; 2023 Jan; 33(1):160-168. PubMed ID: 35134994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy) trial.
    Tsuboi H; Matsumoto I; Hagiwara S; Hirota T; Takahashi H; Ebe H; Yokosawa M; Yagishita M; Takahashi H; Kurata I; Ohyama A; Honda F; Asashima H; Miki H; Umeda N; Kondo Y; Hirata S; Saito K; Tanaka Y; Horai Y; Nakamura H; Kawakami A; Sumida T
    Mod Rheumatol; 2016 Nov; 26(6):891-899. PubMed ID: 27459020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome.
    Machado AC; Dos Santos LC; Fidelix T; Lekwitch I; Soares SB; Gasparini AF; Augusto JV; Junior NC; Trevisani VFM
    Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.
    Fisher BA; Szanto A; Ng WF; Bombardieri M; Posch MG; Papas AS; Farag AM; Daikeler T; Bannert B; Kyburz D; Kivitz AJ; Carsons SE; Isenberg DA; Barone F; Bowman SJ; Espié P; Floch D; Dupuy C; Ren X; Faerber PM; Wright AM; Hockey HU; Rotte M; Milojevic J; Avrameas A; Valentin MA; Rush JS; Gergely P
    Lancet Rheumatol; 2020 Mar; 2(3):e142-e152. PubMed ID: 38263652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome.
    Seror R; Baron G; Camus M; Cornec D; Perrodeau E; Bowman SJ; Bombardieri M; Bootsma H; Gottenberg JE; Fisher B; Hueber W; van Roon JA; Devauchelle-Pensec V; Gergely P; Mariette X; Porcher R; ;
    Ann Rheum Dis; 2022 Jul; 81(7):979-989. PubMed ID: 35393271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
    Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial.
    Felten R; Devauchelle-Pensec V; Seror R; Duffau P; Saadoun D; Hachulla E; Pierre Yves H; Salliot C; Perdriger A; Morel J; Mékinian A; Vittecoq O; Berthelot JM; Dernis E; Le Guern V; Dieudé P; Larroche C; Richez C; Martin T; Zarnitsky C; Blaison G; Kieffer P; Maurier F; Dellal A; Rist S; Andres E; Contis A; Chatelus E; Sordet C; Sibilia J; Arnold C; Tawk MY; Aberkane O; Holterbach L; Cacoub P; Saraux A; Mariette X; Meyer N; Gottenberg JE
    Ann Rheum Dis; 2021 Mar; 80(3):329-338. PubMed ID: 33208345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
    Shao Q; Wang S; Jiang H; Liu L
    Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.